Edwards Lifesciences CorporationEWNYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +8.93% | +9.43% | +6.23% | +10.56% | +14.67% |
| Gross Profit Growth | +12.39% | +7.70% | +6.77% | +9.33% | +10.82% |
| EBITDA Growth | +1.01% | +19.76% | +14.84% | -6.10% | -9.61% |
| Operating Income Growth | +1.18% | -12.36% | +11.05% | +18.15% | +21.25% |
| Net Income Growth | +697.82% | +4.24% | +1.73% | -9.32% | -90.52% |
| EPS Growth | +715.87% | +6.56% | +5.17% | -6.56% | -90.27% |
| EPS Diluted Growth | +714.29% | +6.56% | +5.17% | -8.20% | -90.25% |
| Weighted Average Shares Growth | -1.61% | -2.54% | -2.44% | -2.51% | -2.09% |
| Weighted Average Shares Diluted Growth | -1.87% | -2.70% | -2.70% | -2.71% | -2.07% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -14.51% | -193.34% | +0.00% | -21.88% | +63.08% |
| Free Cash Flow Growth | -10.19% | -606.57% | +0.00% | -15.80% | +61.36% |
| Receivables Growth | +1.17% | -12.16% | -14.25% | +8.17% | +10.02% |
| Inventory Growth | +6.95% | +20.28% | -7.74% | +11.42% | +3.32% |
| Asset Growth | +38.42% | +39.43% | +33.75% | +33.56% | +2.32% |
| Book Value per Share Growth | +45.73% | +54.28% | +45.86% | +45.43% | +9.19% |
| Debt Growth | +2.26% | +2.17% | +0.03% | +1.39% | -0.91% |
| R&D Expense Growth | +4.37% | +11.98% | -0.82% | +1.32% | +10.77% |
| SG&A Expenses Growth | +10.34% | +18.07% | +8.71% | +11.36% | +22.12% |